Email this page
Print
Bookmark and share
Bigger
Smaller
RSS feedFor consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
Quick Links
Articles on hydromorphone from NPS RADARArticles on hydromorphone from NPS RADAR
| Title | Content Type | Date | Description |
|---|---|---|---|
| Hydromorphone prolonged-release tablets (Jurnista) for chronic severe disabling pain | Professional publication - NPS RADAR - Brief item | 2009-05-01 00:00:00 | Hydromorphone prolonged-release (Jurnista), a once-daily long-acting opioid, was listed on the Pharmaceutical Benefits Scheme on 1 May 2009. It is available as a restricted benefit for chronic severe disabling cancer or non-cancer pain not responding to non-opioid analgesics. |
View all RADAR articles by date, by therapeutic topic, or by active ingredient, or find out more about NPS RADAR.
NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.
Date published: 2009-10-30 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
